PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Amoxicillin

Drugs in development · updated 30 October 2026

Amoxicillin: clinical trials and development status

Other names and codes: Moxatag, Amoxil, Larotid

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Amoxicillin is in 29 active clinical trials (recruiting or ongoing, phases I–III) for 22 diseases. The most advanced phase is III.

29Active trials
IIIMost advanced phase
22Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Amoxicillin and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Community-acquired pneumoniaIII3NCT06229288
InfectionII–III3NCT07202091
Helicobacter infectionIII2NCT07904429
LeukemiaII–III2NCT07202091
LymphomaII–III2NCT07202091
NeoplasmII–III2NCT07202091
Plasma cell neoplasmII–III2NCT07202091
AgammaglobulinemiaII–III1NCT05678621
AtrophyIII1NCT02407119
BacteremiaIII1NCT05224401
Chronic subdural hematomaII–III1NCT07556991
Drug HypersensitivityIII1NCT06303128
Hematologic neoplasmII–III1NCT05678621
Lower back painIII1NCT06771492
Stomach neoplasmIII1NCT02407119
Treponemal InfectionsIII1NCT06877351
Urinary tract infectionIII1NCT05224401
Appendiceal neoplasmII1NCT02387203
Congenital syphilisII1NCT06921213
Mycobacterium Infections, NontuberculousII1NCT07485010
Pseudomyxoma peritoneiII1NCT02387203
Sclerosing cholangitisEarly I1NCT06197308

Everything on Amoxicillin

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch